Molecular Analysis of the KIT Gene in Gastrointestinal Stromal Tumors With Novel Mutations


ÇALIBAŞI KOÇAL G., BAŞBINAR Y., ALYÜRÜK H., ÇAVAŞ L., Oztop I., Sagol Ö., ...Daha Fazla

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, cilt.22, sa.1, ss.37-45, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/pai.0b013e318284a074
  • Dergi Adı: APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.37-45
  • Anahtar Kelimeler: gastrointestinal stromal tumors, KIT gene, pharmacogenomics, DNA sequencing, bioinformatics, RECEPTOR TYROSINE KINASE, C-KIT, IMATINIB, PROGNOSIS, DOMAIN, GISTS, ASSOCIATION, SUNITINIB, DIAGNOSIS, PDGFRA
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. KIT gene mutations have great importance for GISTs. This study evaluated the relationship between KIT mutations and GIST clinicopathologic features to define region-specific and population-specific differences. Genomic DNA was extracted from 60 GISTs, and polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17. Polymerase chain reaction amplicons were sequenced in both directions. This study represents the first mutation data of the KIT gene in GISTs from a Turkish population and reports novel mutations. The mutation rate in exon 11 (46.7%) was remarkably higher than those of the other exons (8.3% for exon 9; 11.7% for exon 13; 1.7% for exon 17). There was an association between malignancy potential and the presence of KIT mutations (odds ratio=3.18). Cases with mutations in codons W557-K558 in exon 11 had 11-fold greater risk of malignancy when compared with those without a mutation in this exon (odds ratio=11). We report different mutations than those previously reported, which emphasizes the importance of personalized medicine that could be empowered by the use of bioinformatics tools in the diagnostic process and therapeutic approaches.